Setanaxib as a member of the novel drug class of naxibs is a specific dual NOX1 and NOX4 inhibitor, preventing the excessive activation of MAPK pathway induced by Nox1/4-derived ROS, and further leading to the delay or prevention of progression of many cardiovascular disorders including the improvement of doxorubicin-induced cardiotoxicity [193]. The gene discussed is NOX1; the disease is cardiovascular disorder.